These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A Bayesian approach for estimating bioterror attacks from patient data. Ray J; Marzouk YM; Najm HN Stat Med; 2011 Jan; 30(2):101-26. PubMed ID: 20963771 [TBL] [Abstract][Full Text] [Related]
5. Blood donor screening for agents of bioterror: more questions than answers. Katz LM; Sayers M Transfusion; 2005 Mar; 45(3):290-2. PubMed ID: 15752144 [No Abstract] [Full Text] [Related]
6. [Detection and identification of a biological attack]. Orr-Urtreger A; Katz LH; Brenner B Harefuah; 2002 May; 141 Spec No():29-30, 122. PubMed ID: 12170550 [TBL] [Abstract][Full Text] [Related]
7. Donor screening for agents of bioterror. Schmidt M; Roth WK; Seifried E; Hourfar MK Transfusion; 2006 Apr; 46(4):678; author reply 678-9. PubMed ID: 16584448 [No Abstract] [Full Text] [Related]
8. Nucleic acid test screening of blood donors for orthopoxviruses can potentially prevent dispersion of viral agents in case of bioterrorism. Schmidt M; Roth WK; Meyer H; Seifried E; Hourfar MK Transfusion; 2005 Mar; 45(3):399-403. PubMed ID: 15752158 [TBL] [Abstract][Full Text] [Related]
9. Modeling the logistics of response to anthrax bioterrorism. Zaric GS; Bravata DM; Cleophas Holty JE; McDonald KM; Owens DK; Brandeau ML Med Decis Making; 2008; 28(3):332-50. PubMed ID: 18349432 [TBL] [Abstract][Full Text] [Related]
10. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? Stramer SL; Zou S; Notari EP; Foster GA; Krysztof DE; Musavi F; Dodd RY Transfusion; 2012 Feb; 52(2):440-6. PubMed ID: 21810101 [TBL] [Abstract][Full Text] [Related]
11. New FDA test detects fake bioterror agents. FDA Consum; 2006; 40(6):33. PubMed ID: 17333564 [TBL] [Abstract][Full Text] [Related]
12. Bioterrorism watch. They don't call it bioterror for nothing: fear is the foe when anthrax spores are found within hospital walls. Hosp Peer Rev; 2002 Jun; 27(6):suppl 1-3. PubMed ID: 12068508 [No Abstract] [Full Text] [Related]
13. Cost-effectiveness of additional blood screening tests in the Netherlands. Borkent-Raven BA; Janssen MP; van der Poel CL; Bonsel GJ; van Hout BA Transfusion; 2012 Mar; 52(3):478-88. PubMed ID: 21880046 [TBL] [Abstract][Full Text] [Related]
14. Limited effectiveness of donor deferral registries for transfusion-transmitted disease markers. Cable R; Musavi F; Notari E; Zou S; Transfusion; 2008 Jan; 48(1):34-42. PubMed ID: 17894796 [TBL] [Abstract][Full Text] [Related]
15. Pre-donation screening of intending blood donors for antibodies to infectious agents in a Nigerian tertiary health institution: a pilot study. Salawu L; Murainah HA Afr J Med Med Sci; 2006 Dec; 35(4):453-6. PubMed ID: 17722812 [TBL] [Abstract][Full Text] [Related]
16. Modeling on the Effects of Deliberate Release of Aerosolized Inhalational Costantino V; Bahl P; Doolan C; de Silva C; Heslop D; Chen X; Lim S; MacIntyre CR Health Secur; 2023; 21(1):61-69. PubMed ID: 36695665 [TBL] [Abstract][Full Text] [Related]
17. Update: investigation of bioterrorism-related inhalational anthrax--Connecticut, 2001. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(47):1049-51. PubMed ID: 11808925 [TBL] [Abstract][Full Text] [Related]
20. [Model calculations for HIV screening of blood and plasma donors with a combination of 2 screening tests: test strategies, validity, costs and effectiveness]. Abel U; Kiessig ST Infusionsther Transfusionsmed; 1995 Jun; 22(3):175-85. PubMed ID: 7543784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]